(Q37505871)

20 August 2017

1 reference

title

Comorbidity and its impact in adult patients with attention-deficit/hyperactivity disorder: a primary care perspective (English)

1 reference

attention deficit hyperactivity disorder

20 August 2017

1 reference

1 reference

1 reference

Thomas Babcock

1

1 reference

PubMed ID

19491543

20 August 2017

Craig S Ornstein

series ordinal

2

1 reference

PubMed ID

19491543

20 August 2017

language of work or name

English

0 references

publication date

1 May 2009

1 reference

20 August 2017

Postgraduate Medicine

1 reference

20 August 2017

121

1 reference

20 August 2017

3

1 reference

20 August 2017

73-82

1 reference

Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication

20 August 2017

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2005

Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2005

The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2005

Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2005

Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2005

Revisiting the association between attention-deficit/hyperactivity disorder and anxiety disorders: a familial risk analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2005

Can adults with attention-deficit/hyperactivity disorder be distinguished from those with comorbid bipolar disorder? Findings from a sample of clinically referred adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2005

Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: a case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2005

The role of comorbid major depressive disorder in the clinical presentation of adult ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2005

Attention-deficit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2005

What are adolescent antecedents to antisocial personality disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2005

Predicting future antisocial personality disorder in males from a clinical assessment in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2005

Juvenile delinquency and attention deficit disorder: boys' developmental trajectories from age 3 to age 15.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2005

Gender differences in children with ADHD, ODD, and co-occurring ADHD/ODD identified in a school population

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2005

Males on the life-course-persistent and adolescence-limited antisocial pathways: follow-up at age 26 years

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2005

Correlates of ADHD among children in pediatric and psychiatric clinics.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2005

Diagnostic issues for adolescents and adults with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2005

Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2005

The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2005

Psychopathological rating scales for diagnostic use in adults with attention-deficit/hyperactivity disorder (ADHD).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2005

Atomoxetine and Adult Attention-Deficit/Hyperactivity Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2005

A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2005

Neuropsychological correlates of methylphenidate treatment in adult ADHD with and without depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2005

A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2005

Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2005

ADHD comorbidity findings from the MTA study: comparing comorbid subgroups

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2005

Effect of anxiety on cognition, behavior, and stimulant response in ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2005

Psychiatric comorbidity in adults with attention-deficit/hyperactivity disorder (ADHD).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2005

A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2005

Combination pharmacotherapy for adult ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2005

Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2005

An open-label pilot study of methylphenidate in the treatment of cocaine dependent patients with adult attention deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2005

Bupropion treatment for cocaine abuse and adult attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2005

A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2005

21 January 2018

Identifiers

DOI

10.3810/PGM.2009.05.2005

1 reference

20 August 2017

1 reference

PubMed ID

19491543